Global Perspective of Paediatric Pharmacovigilance and its Importance: Where Have We Reached?

Abstract

Pharmacovigilance is a tool proposed during the post-marketing process of the pharmaceutical product lifecycle to monitor drug safety in everyday life and to identify adverse drug reactions. The identification of adverse reactions, however, is a significant cause of concern and a challenge to pharmacovigilance structures. Regulators use three basic principles in determining the risk-benefit balance to decide whether to approve a drug or a biological product and to maintain it on the market: safety, quality and effectiveness. In particular, paediatric patients, especially new-borns and infants, are at risk of drug-related adverse reactions. Drugs are also prescribed in an unlicensed and/or off-label manner to new-borns, infants and teenagers, leading paediatric patients to a higher risk of experiencing adverse drug reactions (ADRs). ADRs in children < 2 years of age are often reported and can often be alarming. The practise of paediatric pharmacovigilance needs to be strengthened by stimulating spontaneous paediatric reporting and successful post-marketing surveillance. The current study highlights the importance of paediatric pharmacovigilance and the role of different stakeholders like healthcare providers, regulators, and consumers in increasing the ADR reporting rate. Also, it discusses the pharmacovigilance tools and various initiatives that are taken by various regulatory authorities like the United States, the United Kingdom, Japan, and India.

Безопасность Назначения Лекарственных Средств Детям: Роль Врача И Фармацевта

“…Согласно рекомендациям ВОЗ, для предупреждения таких случаев уже более двух десятилетий для упаковки лекарства используют специальные контейнеры, трудно поддающиеся открыванию именно детьми. Следует отдавать предпочтение современным дозированным лекарственным формам (например, дозированным спреям, а не назальным каплям), особенно деконгестантам, чтобы снизить риски передозировки и развития системных нежелательных реакций [15]. Решение проблемы безопасного применения ЛС у детей -сложная задача, которая предполагает использование, как имеющихся ресурсов, так и новых подходов, специалистов и инструментов.…”